ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PHAT vs OVID // EV/EBITDA & P/E VALUATION

Phathom Pharmaceuticals Inc. (NASDAQ) VS. Ovid Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PHAT 3 — OVID 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHAT VS. OVID) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PHAT OVID SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -28.50% -6.50 OVID /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -7.67% — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -0.10% -60.00% +59.90 PHAT /net-margins <GO>
Revenue Growth (YoY) 180.00% 180.00% 0.00 TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 11.46 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 PHAT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.5 56.1 -22.61 OVID /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $503.2M $500.0M $3.2M PHAT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PHAT REV OVID REV PHAT GROSS % OVID GROSS % PHAT FCF OVID FCF
FY 2025 $175.1M $7.3M 87.1% — -$167.0M -$38.3M
FY 2024 $55.3M $566.0K 85.6% — -$266.9M -$56.0M
FY 2023 $682.0K $392.0K — — -$137.6M -$45.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHAT // BETA —
OVID // BETA —